| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
British Medical Bulletin 48:368-400 (1992)
© 1992 The British Council
research-article |
HRT: An analysis of benefits, risks and costs
Oxford Hormone Replacement Therapy Study Group, Department of Public Health & Primary Care, University of Oxford Oxford, UK
Abstract
A cost-effectiveness analysis of hormone replacement therapy (HRT) was undertaken to assess the relative benefits of different treatment strategies, and to identify which factors most influence cost-effectiveness. The current lack of conclusive evidence on the effects of HRT, especially in relation to combined therapy and cardiovascular disease, necessitated the use of a large number of assumptions in our model. In terms of net health benefits, the potential reduction in cardiovascular disease would have greatest impact, and would overshadow any small increase in breast cancer risk possibly associated with long-term use. Net expenditure by the NHS will depend critically on the direct costs of treatment, rather than on any indirect costs incurred or averted as a result of side-effects. In terms of cost-effectiveness, long-term prophylactic treatment of hysterectomised women and treatment of symptomatic women with a uterus compare favourably with other accepted health care interventions.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
T. B Gosden and D. J Torgerson Economics notes: Converting international cost effectiveness data to UK prices BMJ, August 3, 2002; 325(7358): 275 - 276. [Full Text] [PDF] |
||||
![]() |
D.H. Barlow Cost-effectiveness modelling Hum. Reprod., December 1, 2001; 16(12): 2479 - 2480. [Full Text] [PDF] |
||||
![]() |
D. Hosking, C. E.D. Chilvers, C. Christiansen, P. Ravn, R. Wasnich, P. Ross, M. McClung, A. Balske, D. Thompson, M. Daley, et al. Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age N. Engl. J. Med., February 19, 1998; 338(8): 485 - 492. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Torgerson, R. E. Thomas, M. K. Campbell, and D. M. Reid Randomized Trial of Osteoporosis Screening: Use of Hormone Replacement Therapy and Quality-of-Life Results Arch Intern Med, October 13, 1997; 157(18): 2121 - 2125. [Abstract] [PDF] |
||||
![]() |
T. Marshall Hormone replacement therapy for all? BMJ, November 9, 1996; 313(7066): 1205c - 1205. [Full Text] |
||||
![]() |
S. Panico, R. Galasso, E. Celentano, L. Frova, R. Capocaccia, and F. Berrino Hormone replacement therapy may not always be right choice to prevent cardiovascular disease BMJ, September 14, 1996; 313(7058): 687 - 687. [Full Text] |
||||
![]() |
A J Isaacs, A R Britton, and K. McPherson Utilisation of hormone replacement therapy by women doctors BMJ, November 25, 1995; 311(7017): 1399 - 1401. [Abstract] [Full Text] |
||||
![]() |
N. M. Kaplan The Treatment of Hypertension in Women Arch Intern Med, March 27, 1995; 155(6): 563 - 567. [Abstract] [PDF] |
||||
![]() |
F French, D Torgerson, and R W Porter Overestimation of cost savings: in prevention of osteoporosis BMJ, January 8, 1994; 308(6921): 138 - 138. [Full Text] |
||||



